Cerecor's application for CERC-802, indicated for the treatment of mannose-phosphate isomerase deficiency, a rare inherited metabolic disorder, was granted Fast Track status by the FDA.
FDA fast-tracks review of Cerecor's drug for rare metabolic disorder
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.